Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/126096
Title: Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease
Author: Höftberger, Romana
Sepulveda, María
Armangué, Thaís
Blanco, Yolanda
Rostásy, Kevin
Cobo Calvo, Álvaro
Olascoaga, Javier
Ramió Torrentà, Lluís
Reindl, Markus
Benito León, Julián
Casanova, Bonaventura
Arrambide, Georgina
Sabater, Lidia
Graus Ribas, Francesc
Dalmau Obrador, Josep
Saiz Hinajeros, Albert
Keywords: Malalties del nervi òptic
Malalties del sistema nerviós central
Optic nerve diseases
Central nervous system diseases
Issue Date: 1-Jun-2015
Publisher: Sage Publications Ltd
Abstract: Objective: We aimed to report the frequency and implications of antibodies to myelin oligodendrocyte glycoprotein (MOG-ab) in adults with demyelinating syndromes suspicious for neuromyelitis optica (NMO). Methods: Samples from 174 patients (48 NMO, 84 longitudinally extensive myelitis (LETM), 39 optic neuritis (ON), and three acute disseminated encephalomyelitis (ADEM) who presented initially with isolated LETM) were retrospectively examined for AQP4-ab and MOG-ab using cell-based assays. Results: MOG-ab were found in 17 (9.8%) patients, AQP4-ab in 59 (34%), and both antibodies in two (1.1%). Among the 17 patients with MOG-ab alone, seven (41%) had ON, five (29%) LETM, four (24%) NMO, and one (6%) ADEM. Compared with patients with AQP4-ab, those with MOG-ab were significantly younger (median: 27 vs. 40.5 years), without female predominance (53% vs. 90%), and the clinical course was more frequently monophasic (41% vs. 7%) with a benign outcome (median Expanded Disability Status Scale: 1.5 vs. 4.0). In eight patients with paired serum-cerebrospinal fluid (CSF) samples, five had MOG-ab in both samples and three only in serum. Antibody titres did not differ among clinical phenotypes or disease course. MOG-ab remained detectable in 12/14 patients (median follow-up: 23 months) without correlation between titres' evolution and outcome. Conclusion: MOG-ab identify a subgroup of adult patients with NMO, LETM and ON that have better outcome than those associated with AQP4-ab. MOG-ab are more frequently detected in serum than CSF and the follow-up of titres does not correlate with outcome.
Note: Versió postprint del document publicat a: https://doi.org/10.1177/1352458514555785
It is part of: Multiple Sclerosis Journal, 2015, vol. 21, num. 7, p. 866-874
Related resource: https://doi.org/10.1177/1352458514555785
URI: http://hdl.handle.net/2445/126096
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
HoftbergerR.pdf82.57 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.